DOCSLIB.ORG

Treatment Emergent Central Sleep Apnea in Patients with Primary Osa Treated with Positive Airway Pressure Vs Mandibular Advancement Device

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment Emergent Central Sleep Apnea in Patients with Primary Osa Treated with Positive Airway Pressure Vs Mandibular Advancement Device TREATMENT EMERGENT CENTRAL SLEEP APNEA IN PATIENTS WITH PRIMARY OSA TREATED WITH POSITIVE AIRWAY PRESSURE VS MANDIBULAR ADVANCEMENT DEVICE. MUNIR AHMED KHAN PGY-3 NULL HYPOTHESIS There is statistically no significant difference in the development of treatment emergent central Sleep Apnea in patients treated with Positive airway pressure vs Mandibular advancement device for primary obstructive Sleep Apnea. “Treatment emergent central sleep apnea is defined as greater than 5 apnea or hypopnea events per hour in a sleep study done while patient is on treatment for OSA” INTRODUCTION: • OSA is characterized by recurrent collapse of the pharyngeal airway during sleep . resulting in substantially reduced or complete cessation of air flow despite ongoing breathing effort. • OSA is a common condition in adults with prevalence rate of 5-10%[1,2] • OSA leads to intermittent disturbances in gas exchange, and fragmented sleep. • Common symptoms include snoring, day time sleepiness, witnessed apneas, fatigue, morning headache and nocturia. • Continuous Positive Airway Pressure (CPAP) therapy is the standard of treatment for OSA. • CPAP therapy for OSA is complicated by occurrence of treatment emergent central sleep apnea. • In a large prospective study, the prevalence during the first night of CPAP titration was 12%. [1,2,3] • However most of these patients had mixed and central apneas during their diagnostic sleep study. • Mandibular advancement device (MAD) is an alternative treatment modality for OSA in patients intolerant to or unwilling to use CPAP. • There have been few case reports of patients developing complex sleep apnea after MAD therapy.[3,4,5] • However these patients had risk factors for development of central sleep apnea. • There had been no studies to determine the incidence of treatment emergent central sleep apnea in patients with OSA that have been treated with MAD. Central Sleep Apnea : Obstructive sleep Apnea Repeated episodes of apnea Repeated Episodes of decreased during sleep resulting from airflow during sleep due to upper temporary loss of ventilator effort airway obstruction and for at least 10 seconds. subsequent ventilator attempts against occluded airway. METHODS: • A retrospective chart review analysis was conducted on patients that were ever placed on MAD therapy in a community sample of patients with OSA. • Demographics and comorbidity status was collected on all patients. • The severity of sleep apnea , sleep fragmentation and degree of hypoxemia was extracted from diagnostic and follow up sleep studies. • Data was abstracted regarding occurrence of central sleep apnea after being placed on MAD. • A matched community sample of patients with OSA and PAP therapy was evaluated and compared for the occurrence of treatment emergent central sleep apnea. • Statistical comparison was done between two groups using Fisher exact test with expected primary outcome was : “To determine if there is any difference in the incidence of treatment emergent central sleep apnea in OSA patients treated with MAD compared to those treated with PAP therapy.” Secondary Outcomes: 1. To determine whether the severity of sleep apnea predicts the development of treatment emergent central sleep apnea. 2.To determine if severity of hypoxemia during sleep study independently predicts occurrence of treatment emergent central events in OSA. 3. To determine if the patients‘ BMI predicts the development of treatment emergent central sleep apnea INCLUSION CRITERIA: • Sleep study demonstrating Obstructive Sleep Apnea. • Patients treated with MAD or CPAP therapy. • MAD patients with sleep study repeated while using MAD. Exclusion Criteria: Patients with central sleep apnea (central apnea index>5/hr) in the diagnostic study. References • 1. Tishler PV, Larkin EK, Schluchter MD, Redline S (2003) Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 289 (17):2230-2237. doi:10.1001/jama.289.17.2230 • 2. Young T, Peppard PE, Gottlieb DJ (2002) Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165 (9):1217-1239 • 3. Cassel W, Canisius S, Becker HF, Leistner S, Ploch T, Jerrentrup A, Vogelmeier C, Koehler U, Heitmann J (2011) A prospective polysomnographic study on the evolution of complex sleep apnea. Eur Respir J 38 (2):329-337. doi:10.1183/09031936.00162009 • 4. Kuzniar TJ, Kovacevic-Ristanovic R, Freedom T (2011) Complex sleep apnea unmasked by the use of a mandibular advancement device. Sleep & breathing = Schlaf & Atmung 15 (2):249-252. doi:10.1007/s11325-010- 0459-8 • 5. Avidan AY, Guilleminault C, Robinson A (2006) The development of central sleep apnea with an oral appliance. Sleep Med 7 (2):187-191. doi:10.1016/j.sleep.2005.06.013 • 6. Gindre L, Gagnadoux F, Meslier N, Fleury B, Gustin JM, Racineux JL (2006) [Central apnea developing during treatment with a mandibular advancement device]. Rev Mal Respir 23 (5 Pt 1):477-480 Results: Comparison between two groups using MAD vs PAP as a treatment modality for the treatment emergent Central Sleep Apnea showed: There was a statistically significant difference in two groups using Fisher exact test. P value =0.0378 Odds Ratio= 2.1211 95% CI 1.0432-4.3129 COMPARISON BETWEEN TWO GROUPS STRATIFIED FOR SEVERITY OF HYPOXIA ON DIAGNOSTIC STUDY: Oxygen saturation>75% on diagnostic study • There was no statistical difference. • P value=0.473. Oxygen saturation <75% on diagnostic study • Statistically significant difference in development of central apnea. • P value 0.0203 COMPARISON BETWEEN TWO GROUPS STRATIFIED FOR SEVERITY OF SLEEP APNEA ON DIAGNOSTIC STUDY. Severity of Sleep Apnea: Determined on the Basis of AHI: Mild: AHI 5>15 Moderate : AHI 15>30 Severe: >30 AHI: Number of hypoxic apneic events/ hr Comparison between two groups with mild OSA on diagnostic study: AHI 5-15 • Statistically significant. • P value= 0.0001 Comparison between two groups with Moderately severe Sleep Apnea on Diagnostic study: AHI 15-30 • Statistically significant • P value= 0.0001 Comparison between two groups with Severe Sleep Apnea on Diagnostic study: AHI>30 on diagnostic study • Statistically non significant • P value=1.000 DIFFERENCE IN TWO GROUPS STRATIFIED FOR BMI BMI 20-30: No statistically significant difference. P value=0.7678 BMI 30-40: Statistically significant difference. P value=0.022 BMI >40 Statistically significant difference . P value=0.0203 DIFFERENCE BETWEEN TWO GROUPS WITH PATIENTS HAVING CHF OR OPIATES DEPENDENCE: There was no incidence of Treatment emergent Central Sleep Apnea in patients with CHF or Opiate Dependence treated with PAP vs MAD in the study Population. CONCLUSIONS: • Statistically significant increased incidence of Treatment Emergent Central Sleep Apnea in patients treated with MAD as compared to PAP for primarily OSA. • Statistically Significant difference in two groups stratified for severity of hypoxia in patients with oxy-hemoglobin saturation less than 75% on diagnostic study. • Statistically significant difference in two groups stratified for severity of OSA on diagnostic study in mild to moderate OSA groups. • Statistically significant difference in two groups stratified for BMI in BMI group 30-40 and >40. • There is no incidence of Central sleep apnea in two groups with CHF and opiate Dependence. Rationale Behind Increased incidence of Treatment emergent sleep apnea in MAD group: Likely PAP-Independent factors: Sleep Fragmentation Propensity for periodic breathing SHORTCOMINGS • Not a multi centric study. • Confounding factors like CAD, ESRD and A-fib were not included in this study. • Follow up sleep study in PAP group included was a titration study and not the study on effective pressure..
Load more

Recommended publications
  • Non-Invasive Ventilation Made Ridiculously Simple
    NON-INVASIVE VENTILATION MADE RIDICULOUSLY SIMPLE Jennifer Newitt, MD 3rd year Pulmonary/Critical Care Fellow Mentor: Patrick Strollo Jr, MD Myth or Fact ?!? Myth or Fact ?!? Treatment for Obstructive Sleep Apnea ■ Lifestyle Modifications – Weight loss, increased fitness – Avoid alcohol, sleep deprivation, sedatives – Lateral position, head of bed elevation ■ Surgical – Upper airway reconstruction (UPP) or tracheostomy – Upper airway stimulation ■ Positive Airway Pressure via mask ■ Oral appliance therapy Treatment for Obstructive Sleep Apnea ■ Lifestyle Modifications – Weight loss, increased fitness – Avoid alcohol, sleep deprivation, sedatives – Lateral position, head of bed elevation ■ Surgical – Upper airway reconstruction (UPP) or trach – Upper airway stimulation ■Positive Positive Airway Pressure Airway via mask Pressure via mask ■ Oral appliance therapy 3 decades later…! Continuous Positive Airway Pressure (CPAP) ■ Continuous level of positive pressure provided to overcome airway obstruction ■ Patient must inhale and exhale over continuous pressure ■ Patient initiates all breaths ■ No additional pressure above level of CPAP is provided Continuous Positive Airway Pressure (CPAP) ■ Fixed CPAP – Fixed level of pressure between 4-20 cm H20 (ex: 10 cm H20) ■ Auto-CPAP – Variable pressure according to patient needs as detected by machine – If apnea, hypopnea, flow limitation, or snoring are detected, pressure is increased until events are eliminated – If no events are detected over set time period, pressure is decreased – Set pressure
    [Show full text]
  • Central Periodic Breathing During Sleep in 74 Patients with Acute Ischemic Stroke - Neurogenic and Cardiogenic Factors
    Siccoli, M M; Valko, P O; Hermann, D M; Bassetti, C L (2008). Central periodic breathing during sleep in 74 patients with acute ischemic stroke - Neurogenic and cardiogenic factors. Journal of Neurology, 255(11):1687-1692. Postprint available at: http://www.zora.uzh.ch University of Zurich Posted at the Zurich Open Repository and Archive, University of Zurich. Zurich Open Repository and Archive http://www.zora.uzh.ch Originally published at: Journal of Neurology 2008, 255(11):1687-1692. Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Central periodic breathing during sleep in 74 patients with acute ischemic stroke - Neurogenic and cardiogenic factors Siccoli, M M; Valko, P O; Hermann, D M; Bassetti, C L Siccoli, M M; Valko, P O; Hermann, D M; Bassetti, C L (2008). Central periodic breathing during sleep in 74 patients with acute ischemic stroke - Neurogenic and cardiogenic factors. Journal of Neurology, 255(11):1687-1692. Postprint available at: http://www.zora.uzh.ch Posted at the Zurich Open Repository and Archive, University of Zurich. http://www.zora.uzh.ch Originally published at: Journal of Neurology 2008, 255(11):1687-1692. CENTRAL PERIODIC BREATHING IN 74 PATIENTS WITH ACUTE ISCHEMIC STROKE - NEUROGENIC VERSUS CARDIOGENIC FACTORS Massimiliano M. Siccoli, MD Philipp O. Valko, MD Dirk M. Hermann, MD Claudio L. Bassetti, MD Department of Neurology, University Hospital of Zurich, Switzerland Correspondence: Prof. Claudio L. Bassetti Department of Neurology University Hospital of Zurich Frauenklinikstrasse 26
    [Show full text]
  • Sleep-Apnea-Protocol.Pdf
    Evidence-based Practice Center Systematic Review Protocol Project Title: Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea in Medicare Eligible Patients I. Background Sleep apnea is a common disorder that affects people of all ages. It is characterized by periods of airflow cessation (apnea) or reduced airflow (hypopnea) during sleep. Sleep apnea may be caused by mechanical obstruction of the airways resulting in disturbed airflow patterns, by a central loss of respiratory drive, or a combination of the two (mixed). Obstructive sleep apnea- hypopnea syndrome, more commonly called obstructive sleep apnea (OSA), is the most common type of sleep apnea.1 Definition and severity of obstructive sleep apnea Sleep apnea is primarily diagnosed with sleep tests that measure sleep time (and often other sleep measures) and respiratory events. OSA is distinguished from central sleep apnea by the presence of respiratory effort during episodes of apnea and hypopnea (in contrast with central sleep apnea where respiratory effort is lacking). The severity of OSA is typically quantified by the sum of the number of apneas and hypopneas per hour of sleep, a quantity that has been termed the apnea-hypopnea index (AHI). AHI is often used as part of both diagnosis (and, thus, study inclusion criteria) and as a surrogate measure for health outcomes (also called an intermediate outcome) in studies. The American Academy of Sleep Medicine (AASM) publishes scoring manuals for AHI and other physiological events to characterize OSA. In the United States, AASM is the predominant accrediting institution for sleep laboratories. AASM first published its scoring manual in 1999 (known as the “Chicago” Criteria).2 They have amended their definitions of breathing events, sleep time, and how these are measured multiple times since their first set of criteria, with major revisions in 2007,3 and in 2012.4 Minor revisions have been made almost annually since (the current version is v2.6,5 released in 2020).
    [Show full text]
  • Sleep Apnea Sleep Apnea
    Health and Safety Guidelines 1 Sleep Apnea Sleep Apnea Normally while sleeping, air is moved at a regular rhythm through the throat and in and out the lungs. When someone has sleep apnea, air movement becomes decreased or stops altogether. Sleep apnea can affect long term health. Types of sleep apnea: 1. Obstructive sleep apnea (narrowing or closure of the throat during sleep) which is seen most commonly, and, 2. Central sleep apnea (the brain is causing a change in breathing control and rhythm) Obstructive sleep apnea (OSA) About 25% of all adults are at risk for sleep apnea of some degree. Men are more commonly affected than women. Other risk factors include: 1. Middle and older age 2. Being overweight 3. Having a small mouth and throat Down syndrome Because of soft tissue and skeletal alterations that lead to upper airway obstruction, people with Down syndrome have an increased risk of obstructive sleep apnea. Statistics show that obstructive sleep apnea occurs in at least 30 to 75% of people with Down syndrome, including those who are not obese. In over half of person’s with Down syndrome whose parents reported no sleep problems, sleep studies showed abnormal results. Sleep apnea causing lowered oxygen levels often contributes to mental impairment. How does obstructive sleep apnea occur? The throat is surrounded by muscles that are active controlling the airway during talking, swallowing and breathing. During sleep, these muscles are much less active. They can fall back into the throat, causing narrowing. In most people this doesn’t affect breathing. However in some the narrowing can cause snoring.
    [Show full text]
  • Respiratory Assist Device Appendices a and B
    DRAFT Appendix A Clinical Indications for the Use of Respiratory Assist Device (RAD) Therapy Indications for use of a RAD is divided into four categories: • Restrictive thoracic disorders, e.g., neuromuscular disorders such as amyotrophic lateral sclerosis; • Severe chronic obstructive pulmonary disease (COPD); o Use of a RAD in COPD patients requires, . A facility-based polysomnogram to rule out obstructive sleep apnea in order to initiate Medicare coverage, . A prerequisite trial of noninvasive ventilation without a backup rate, and . Treatment with continuous positive airway pressure devices. • Central sleep apnea, i.e., apnea not due to airway obstruction; and • Obstructive sleep apnea (OSA). Initial Coverage (First 3 Months of Therapy) Medical record must document symptoms characteristic of sleep-associated hypoventilation, e.g.: • Daytime hypersomnolence; • Excessive fatigue; • Morning headache; • Cognitive dysfunction; • Dyspnea, etc.; and • Beneficiary has one (1) of the disorders listed in the Documentation Verification Procedures section below and meets all coverage criteria for that disorder. Continued Coverage (Beyond First 3 Months of Therapy) - E0470 or E0471 Medical records document the beneficiary was re-evaluated on/after the 61st day of therapy demonstrating: • Progress of relevant symptoms; and • Beneficiary usage of the device (average 4 hours per 24 hours) Documentation in supplier’s records includes the following: • Signed and dated physician statement completed no sooner than 61 days after initiating use of the
    [Show full text]
  • Role of the Allergist-Immunologist and Upper Airway Allergy in Sleep-Disordered Breathing
    AAAAI Work Group Report Role of the Allergist-Immunologist and Upper Airway Allergy in Sleep-Disordered Breathing Dennis Shusterman, MD, MPHa, Fuad M. Baroody, MDb, Timothy Craig, DOc, Samuel Friedlander, MDd, Talal Nsouli, MDe, and Bernard Silverman, MD, MPHf; on behalf of the American Academy of Allergy, Asthma & Immunology’s Rhinitis, Rhinosinusitis and Ocular Allergy Committee Work Group on Rhinitis and Sleep-disordered Breathing San Francisco, Calif; Chicago, Ill; Hershey, Pa; Solon, Ohio; Washington, DC; and Brooklyn, NY BACKGROUND: Sleep-disordered breathing in general and RESULTS: Survey results were returned by 339 of 4881 active obstructive sleep apnea in particular are commonly encountered members (7%). More than two-third of respondents routinely conditions in allergy practice. Physiologically, nasal (or asked about sleep problems, believed that sleep-disordered nasopharyngeal) obstruction from rhinitis, nasal polyposis, or breathing was a problem for at least a “substantial minority” adenotonsillar hypertrophy are credible contributors to snoring (10%-30%) of their adult patients, and believed that medical and nocturnal respiratory obstructive events. Nevertheless, therapy for upper airway inflammatory conditions could existing practice parameters largely relegate the role of the potentially help ameliorate sleep-related complaints. Literature allergist to adjunctive treatment in cases of continuous positive review supported the connection between high-grade nasal airway pressure intolerance. congestion/adenotonsillar hypertrophy and obstructive sleep OBJECTIVES: To survey active American Academy of Allergy, apnea, and at least in the case of pediatric patients, supported the Asthma & Immunology members regarding their perceptions use of anti-inflammatory medication in the initial management and practices concerning sleep-disordered breathing in adult and of obstructive sleep apnea of mild-to-moderate severity.
    [Show full text]
  • Policies & Procedures Title: CPAP/Bipap-Non Invasive Ventilation
    Policies & Procedures Title: CPAP/BiPAP-Non Invasive Ventilation (NIV) - Care and Monitoring of the Patient • Post-operative care • Acute respiratory failure Number: 1114 Authorization: Source: Nursing Date Effective: January 2016 [X] SHR Nursing Practice Committee Scope: SHR Acute Urban Any PRINTED version of this document is only accurate up to the date of printing 30-May-16. Saskatoon Health Region (SHR) cannot guarantee the currency or accuracy of any printed policy. Always refer to the Policies and Procedures site for the most current versions of documents in effect. SHR accepts no responsibility for use of this material by any person or organization not associated with SHR. No part of this document may be reproduced in any form for publication without permission of SHR. Overview The following policy applies only to the use of NIV for adult patients with acute respiratory failure (see appendix A, post-operative patients and dyspnea in palliative care patients. It does not apply to the treatment of sleep disordered breathing, chronic, stable respiratory failure or pediatric patients. Definitions: Non-Invasive Ventilation is the provision of ventilatory support through the patient’s upper airway using a mask or similar device. For the purposes of this policy, both continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BiPAP) will be generically referred to as non- invasive ventilation (NIV). Note: See SHR policy 7311-60-024 https://www.saskatoonhealthregion.ca/about/RWPolicies/7311-60- 024.pdf for the application of non-invasive ventilation for acute respiratory failure. Continuous Positive Airway Pressure (CPAP) is a continuous positive airway pressure that is used to provide a patent airway during periods of sleep apnea.
    [Show full text]
  • Effect of Continuous Positive Airway Pressure Versus Supplemental Oxygen on Sleep
    1 Effect of Continuous Positive Airway Pressure versus Supplemental Oxygen on Sleep 2 Quality in Obstructive Sleep Apnea: A placebo-CPAP controlled study 3 4 5 José S. Loredo, MD,a Sonia Ancoli-Israel PhD,b Eui-Joong Kim, MD,c,b 6 Weon Jeong Lim, MD,d,b And Joel E. Dimsdale MDb 7 8 9 From the Department of Medicine,a and the Department of Psychiatry,b University of California, 10 San Diego, the Department of Psychiatry, Eulji University, Daejeon, Korea,c Department of 11 Psychiatry, Ewha Womans University, Seoul, Korea d 12 13 This work was performed at the University of California San Diego 14 15 This work was supported in part by NIH grants HL44915, AG08415, M01 RR00827, HL36005 16 and K23 HL04056 17 18 The authors did not receive any financial support from or were involved with organization(s) 19 with financial interest in the subject matter 20 21 Address correspondence and requests for reprints to Dr. José S. Loredo, UCSD Medical Center 22 Dept. of Medicine, 200 West Arbor Drive, San Diego, CA 92103-0804. 23 Phone: (619) 543-5593. Fax: (619) 543-7519. E-mail: [email protected] 1 24 ABSTRACT 25 Study Objectives: We investigated the short term effectiveness of CPAP and O2 in improving 26 sleep quality in patients with OSA. 27 Design: Randomized, double blinded, placebo-CPAP controlled, parallel study. 28 Setting: General Clinical Research Center at a University Hospital 29 Patients: Seventy-six untreated OSA patients 30 Interventions: Patients were randomized to one of three treatments (CPAP, placebo-CPAP, 31 nocturnal O2 at 3 L/min) for 2-weeks.
    [Show full text]
  • Principles of Practice Parameters for The
    ERJ Express. Published on July 28, 2016 as doi: 10.1183/13993003.01975-2015 TASK FORCE REPORT IN PRESS | CORRECTED PROOF Principles of practice parameters for the treatment of sleep disordered breathing in the elderly and frail elderly: the consensus of the International Geriatric Sleep Medicine Task Force Nikolaus C. Netzer (Chair)1,2, Sonia Ancoli-Israel (Co-chair)3, Donald L. Bliwise4, Stephany Fulda5, Christine Roffe6, Fernanda Almeida7, Hakki Onen8, Fannie Onen9, Friedhart Raschke10, Miguel Angel Martinez Garcia11 and Helmut Frohnhofen12 Affiliations: 1Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Dept of Sports Science, Faculty of Psychology and Sports Science, University Innsbruck, Austria. 2Division of Sports Medicine and Rehabilitation, Dept of Medicine, University Hospitals Ulm, Ulm, Germany. 3Depts of Psychiatry and Medicine, University of California, San Diego, CA, USA. 4Sleep Program, Dept of Neurology, Emory University, Atlanta, GA, USA. 5Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Lugano, Switzerland. 6Institute for Science and Technology in Medicine, Keele University, Keele, UK. 7Dental Medical School, University of British Colombia, Vancouver, BC, Canada. 8Geriatric Sleep Center, Edouard Herriot University Hospital, HCL, Lyon, France. 9Dept of Geriatrics, Bichat University Hospital, APHP and INSERM U669, Paris, France. 10Institute for Rehabiltation Research, Hospital Norderney, Norderney, Germany. 11Respiratory Dept, La Fe University and Polytechnic Hospital, Valencia, Spain. 12Dept of Geriatric Medicine, Kliniken Essen Mitte, Essen, Germany. Correspondence: Nikolaus C Netzer, Hermann Buhl Institute for Hypoxia and Sleep Medicine Research, Ghersburg Clinic for Geriatric Rehabilitation, Ghersburgstr. 9, 83043 Bad Aibling, Germany. Email: [email protected] ABSTRACT Sleep disordered breathing (SDB) is a leading cause of morbidity worldwide.
    [Show full text]
  • The Effect of Continuous Positive Airway Pressures on Lung Volumes
    Paraplegia (1996) 34, 54- 58 © 1996 International Medical Society of Paraplegia All rights reserved 0031-1758/96 $12.00 The effect of continuous positive airway pressures on lung volumes in tetraplegic patients 2 LA Harveyl and ER Ellis 2 1 Physiotherapy Department, The Prince Henry Hospital, Sydney; School of Physiotherapy, Faculty of Health Sciences, The University of Sydney, Sydney, Australia Continuous positive airway pressure (CPAP) is widely advocated for the treatment of respiratory complications. However the effects of CPAP on the respiratory function of tetraplegic patients have not yet been investigated. The purpose of this study was to examine the effects of breathing with different levels of CPAP on the relationship between closing volume (CV) and functional residual capacity (FRC) in ten recently injured, but otherwise healthy tetraplegic patients with lesions between the fourth and eighth cervical segments. Lung volumes were measured before, during and after 32 min of zero end-expiratory pressure and 5 and 10 cm H20 of CPAP. FRC was measured by the open-circuit nitrogen washout method and CV was measured by the single breath nitrogen washout method. FRC was unaffected by zero end-expiratory pressure, but both 5 cm H20 and 10 cm H20 of CPAP caused significant increases in FRC. FRC returned to pre-CPAP values by the first minute after removal of 5 and 10 cm H20 of CPAP. We were unable to measure CVs in any subjects. It was concluded that 5 and 10 cm H20 of CPAP increase FRC in healthy tetraplegic individuals, but that these increases are rapidly lost with the subsequent removal of CPAP.
    [Show full text]
  • Practice Parameters for the Use of Continuous and Bilevel Positive
    PRACTICE PARAMETER Practice Parameters for the Use of Continuous and Bilevel Positive Airway Pressure Devices to Treat Adult Patients With Sleep-Related Breathing Disorders An American Academy of Sleep Medicine Report Clete A. Kushida, MD, PhD1; Michael R. Littner, MD2; Max Hirshkowitz, PhD3; Timothy I. Morgenthaler, MD4; Cathy A. Alessi, MD5; Dennis Bailey, DDS6; Brian Boehlecke, MD, MSPH7; Terry M. Brown, DO8; Jack Coleman, Jr., MD9; Leah Friedman, PhD10; Sheldon Kapen, MD11; Vishesh K. Kapur, MD, MPH12; Milton Kramer, MD13; Teofilo Lee-Chiong, MD14; Judith Owens, MD15; Jeffrey P. Pancer, DDS16; Todd J. Swick, MD17; Merrill S. Wise, MD18 1Stanford University Center of Excellence for Sleep Disorders, Stanford, CA; 2VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Sepulveda, CA; 3Baylor College of Medicine and VA Medical Center, Houston, TX; 4Mayo Sleep Disorders Center, Mayo Clinic, Rochester, MN; 5UCLA/Greater Los Angeles Healthcare System, Sepulveda, CA; 6Englewood, Colorado; 7University of North Carolina, Chapel Hill, NC; 8St. Joseph Memorial Hospital, Murphysboro, IL; 9Middle Tennessee ENT, Murfreesboro, TN; 10Stanford University School of Medicine, Stan- ford, CA; 11VA Medical Center and Wayne State University, Detroit, MI; 12University of Washington Sleep Disorder Center, Seattle, WA; 13Maimoides Medical Center, Psychiatry Department, Brooklyn, NY and New York University School of Medicine, New York, NY; 14National Jewish Medical and Research Center, Sleep Clinic, Denver, CO; 15Department of Pediatrics, Rhode Island Hospital, Providence, RI; 16Toronto, Ontario, CN; 17Houston, TX; 18Houston, TX Summary: Positive airway pressure (PAP) devices are used to treat pa- studies are usually adequate. 4) CPAP usage should be monitored objec- tients with sleep related breathing disorders (SRBD) including obstructive tively to help assure utilization.
    [Show full text]
  • Sleep Apnea and the Brain: Neurocognitive and Emotional Considerations
    Vitale et al. J Sleep Disord Manag 2016, 2:008 Volume 2 | Issue 1 Journal of Sleep Disorders and Management Review Article: Open Access Sleep Apnea and the Brain: Neurocognitive and Emotional Considerations Gregory John Vitale*, Kimberly Capp, Kimberly Ethridge, Maggie S. Lorenzetti, Mary Jef- frey, John Skicki and Ashley Stripling College of Psychology, Nova Southeastern University, Florida, USA *Corresponding author: Gregory John Vitale, College of Psychology, Nova Southeastern University, 3301 College Ave., Fort Lauderdale, Florida, 33314, USA, Tel: 9548298479, E-mail: [email protected] by utilizing a sleep diagnosis tool, called a polysomnography, to rule Abstract out other sleep disturbances and determine an individual’s apnea- Sleep apnea research has become increasingly relevant to the hypopnea index (AHI). The AHI is based on the number of apnea/ field of psychology. Although the physiological sequelae have hypopnea episodes that occur during a one-hour period of sleep been researched extensively, and treatment options are now and is used to indicate severity of the disorder. An AHI above 5 available for those diagnosed, much is left to be done. Specifically, but less than 15 is considered to be in the mild and impacts 3-28% to date, the cognitive and psychological consequences of sleep apnea have received less attention. As such, this paper serves of individuals, while an AHI above 15 is considered moderate and to review the current state of the literature and presents relevant impacts 1-14% of individuals [1]. Cases of 30 or more episodes per neuropsychological and emotional domains. Given that sleep hour are considered severe and are almost always associated with apnea may cause psychological dysfunction over-and-above those intensified sequelae (e.g.
    [Show full text]